The U.S. healthcare supply chain is one of the most secure and sophisticated in the world, routinely
enabling the safe and efficient delivery of medicines. At the center of this supply chain, distributors are uniquely positioned to perform due diligence to help support the security of the controlled substances they deliver to their customers.
Healthcare distributors that handle controlled substances and list I chemicals are subject to DEA and state requirements under state and federal Controlled Substances Acts. These requirements are usually aimed at preventing diversion and other criminal activities.
While the government’s duty is to prevent, manage and prosecute drug diverters, healthcare distributors — along with manufacturers, pharmacies and healthcare practitioners — share this mission and responsibility to continuously monitor, protect and enhance processes and practices to reduce the diversion of controlled substances.
HDMA supports efforts to prevent drug diversion such as “suspicious orders” monitoring and reporting programs. HDMA recognizes that increased abuse and diversion of controlled substances threaten patient safety and the security of the healthcare supply chain.